Home
»
Press Room
»
Dengue Testing Market Size To Reach $822.61Mn By 2030

Dengue Testing Market Size To Reach $822.61 Million By 2030

May 2025 | Report Format: Electronic (PDF)

Dengue Testing Market Growth & Trends

The global dengue testing market size is expected to reach USD 822.61 million by 2030, registering a CAGR of 5.22% from 2025 to 2030, according to a new report by Grand View Research, Inc. Factors such as urbanization, climate change, and increased international travel have expanded the habitats of Aedes mosquitoes, the primary vectors for dengue transmission. For instance, in 2023, India reported nearly 300,000 dengue cases, highlighting the disease's growing prevalence in Asia-Pacific region. This escalating incidence necessitates the development and deployment of efficient diagnostic tools to enable early detection and prompt treatment, thereby reducing morbidity and mortality associated with the disease.

Innovations in diagnostic technologies have significantly improved the accuracy and speed of dengue detection. The introduction of advanced methods such as enzyme-linked immunosorbent assays (ELISA), reverse transcription-polymerase chain reaction (RT-PCR), and rapid antigen tests has revolutionized the field. These technologies offer high sensitivity and specificity, enabling healthcare providers to diagnose dengue infections promptly. Moreover, the development of point-of-care testing devices facilitates on-site diagnostics, crucial in remote or resource-limited settings. Such advancements not only enhance patient outcomes but also contribute to controlling the spread of the disease.

Governmental and international efforts play a pivotal role in bolstering the dengue testing market. In August 2024, the United States Agency for International Development (USAID) donated dengue and other arbovirus test kits, valued at USD 20,000, to the Caribbean Public Health Agency (CARPHA) to enhance regional outbreak response. Such initiatives underscore the commitment to strengthening diagnostic capacities in vulnerable regions. Additionally, regulatory bodies like the U.S. Food and Drug Administration (FDA) have expedited the approval of innovative diagnostic solutions, such as bioMérieux's BIOFIRE FILMARRAY Tropical Fever Panel, which received Special 510(k) clearance in December 2024. These concerted efforts facilitate the availability and adoption of advanced diagnostic tools globally.

Heightened awareness about dengue fever and its implications has led to increased demand for diagnostic testing. Public health campaigns and educational programs have been instrumental in informing communities about the symptoms, transmission, and prevention of dengue. This awareness encourages individuals to seek timely medical attention, thereby necessitating efficient diagnostic services. Furthermore, informed communities are more likely to participate in vector control initiatives, indirectly contributing to disease management. The emphasis on education and awareness thus plays a critical role in driving the diagnostics market.

The development and availability of rapid diagnostic test (RDT) kits have transformed dengue detection, especially in endemic regions. These kits offer quick results, often within minutes, facilitating immediate clinical decisions. In August 2023, Fujifilm launched its revolutionary Dengue NS1Ag Test Kit, utilizing proprietary silver amplification technology to enable early diagnosis. Such innovations are crucial in mitigating disease severity and reducing mortality rates. The convenience, affordability, and efficiency of RDTs make them indispensable tools in the global fight against dengue, thereby propelling market growth.

key Request a free sample copy or view report summary: Dengue Testing Market Report

Dengue Testing Market Report Highlights

Based on product, the ELISA-based tests segment accounted for the largest market share of 44.94% in 2024, driven by their high sensitivity, specificity, and ability to detect both dengue antigens (NS1) and antibodies (IgM and IgG).
Based on service type, the centralized service segment led the market with a 59.93% revenue share in 2024, driven by the increasing demand for accurate and comprehensive testing solutions. Centralized laboratories, primarily located in hospitals and diagnostic centers, offer advanced diagnostic capabilities, including ELISA and RT-PCR tests, which are essential for confirming dengue infections
Based on end use, the clinical labs segment dominated the market with a revenue share of 44.16% in 2024. Growth is driven by increased investments in laboratory automation, high?throughput ELISA, and RT?PCR platforms, enabling same?day turnaround.
In 2024, Asia Pacific led the global market with a share of 31.57%, owing to endemic dengue transmission in India, Indonesia, and Thailand. National vector control programs (e.g., India’s NVBDCP) fund ELISA and RT?PCR in regional labs, while community health centers deploy POC NS1 rapid tests.